-
Je něco špatně v tomto záznamu ?
Pharmacological targeting of CDK9 in cardiac hypertrophy
V. Krystof, I. Chamrád, R. Jorda, J. Kohoutek,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
19757441
DOI
10.1002/med.20172
Knihovny.cz E-zdroje
- MeSH
- cyklin T chemie MeSH
- cyklin-dependentní kinasa 9 antagonisté a inhibitory chemie metabolismus MeSH
- inhibitory proteinkinas chemie metabolismus farmakologie terapeutické užití MeSH
- kardiomegalie farmakoterapie enzymologie MeSH
- lidé MeSH
- molekulární sekvence - údaje MeSH
- racionální návrh léčiv MeSH
- sekvence aminokyselin MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Cardiac hypertrophy allows the heart to adapt to workload, but persistent or unphysiological stimulus can result in pump failure. Cardiac hypertrophy is characterized by an increase in the size of differentiated cardiac myocytes. At the molecular level, growth of cells is linked to intensive transcription and translation. Several cyclin-dependent kinases (CDKs) have been identified as principal regulators of transcription, and among these CDK9 is directly associated with cardiac hypertrophy. CDK9 phosphorylates the C-terminal domain of RNA polymerase II and thus stimulates the elongation phase of transcription. Chronic activation of CDK9 causes not only cardiac myocyte enlargement but also confers predisposition to heart failure. Due to the long interest of molecular oncologists and medicinal chemists in CDKs as potential targets of anticancer drugs, a portfolio of small-molecule inhibitors of CDK9 is available. Recent determination of CDK9's crystal structure now allows the development of selective inhibitors and their further optimization in terms of biochemical potency and selectivity. CDK9 may therefore constitute a novel target for drugs against cardiac hypertrophy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026024
- 003
- CZ-PrNML
- 005
- 20121210093049.0
- 007
- ta
- 008
- 120817s2010 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1002/med.20172 $2 doi
- 035 __
- $a (PubMed)19757441
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Krystof, Vladimír $u Faculty of Science, Laboratory of Growth Regulators, Palacký University & Institute of Experimental Botany AS CR, Slechtitelů 11, Olomouc 783 71, Czech Republic. vladimir.krystof@upol.cz
- 245 10
- $a Pharmacological targeting of CDK9 in cardiac hypertrophy / $c V. Krystof, I. Chamrád, R. Jorda, J. Kohoutek,
- 520 9_
- $a Cardiac hypertrophy allows the heart to adapt to workload, but persistent or unphysiological stimulus can result in pump failure. Cardiac hypertrophy is characterized by an increase in the size of differentiated cardiac myocytes. At the molecular level, growth of cells is linked to intensive transcription and translation. Several cyclin-dependent kinases (CDKs) have been identified as principal regulators of transcription, and among these CDK9 is directly associated with cardiac hypertrophy. CDK9 phosphorylates the C-terminal domain of RNA polymerase II and thus stimulates the elongation phase of transcription. Chronic activation of CDK9 causes not only cardiac myocyte enlargement but also confers predisposition to heart failure. Due to the long interest of molecular oncologists and medicinal chemists in CDKs as potential targets of anticancer drugs, a portfolio of small-molecule inhibitors of CDK9 is available. Recent determination of CDK9's crystal structure now allows the development of selective inhibitors and their further optimization in terms of biochemical potency and selectivity. CDK9 may therefore constitute a novel target for drugs against cardiac hypertrophy.
- 650 _2
- $a sekvence aminokyselin $7 D000595
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kardiomegalie $x farmakoterapie $x enzymologie $7 D006332
- 650 _2
- $a cyklin T $x chemie $7 D056906
- 650 _2
- $a cyklin-dependentní kinasa 9 $x antagonisté a inhibitory $x chemie $x metabolismus $7 D042863
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a molekulární sekvence - údaje $7 D008969
- 650 _2
- $a inhibitory proteinkinas $x chemie $x metabolismus $x farmakologie $x terapeutické užití $7 D047428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Chamrád, Ivo
- 700 1_
- $a Jorda, Radek
- 700 1_
- $a Kohoutek, Jirí
- 773 0_
- $w MED00003265 $t Medicinal research reviews $x 1098-1128 $g Roč. 30, č. 4 (2010), s. 646-66
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/19757441 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121210093126 $b ABA008
- 999 __
- $a ok $b bmc $g 948066 $s 783370
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 30 $c 4 $d 646-66 $i 1098-1128 $m Medicinal research reviews $n Med Res Rev $x MED00003265
- LZP __
- $a Pubmed-20120817/10/03